Promedior, Inc. Email Format

Biotechnology ResearchUnited States11-50 Employees

Promedior, Inc. is a biotechnology research company based in the United States that operates within the clinical-stage segment of the biopharma landscape. The firm focuses on developing therapies for fibrotic diseases, with its work positioned at the intersection of discovery and clinical development in a specialty area of biotechnology. While the company is small in size, its activities reflect a strategy centered on advancing therapeutic candidates through early to mid-stage development for complex fibrotic conditions. Promedior’s existence as a player in this field is further evidenced by its involvement in strategic transactions within the industry, illustrating a track record that has attracted attention from larger pharmaceutical organizations.

Recent corporate developments indicate that Promedior has undergone acquisition activity within the broader biotech ecosystem, with Roche ultimately acquiring the company and its pipeline. This context situates Promedior within a network of major industry players and highlights the potential value recognized by larger biopharma firms seeking to augment their fibrosis portfolios. The company’s location in the United States and its focus on a highly specialized therapeutic area suggest a research-centric operation aimed at advancing clinical candidates through pivotal stages of development, serving a market of partners and collaborators in pursuit of new fibrosis treatments.

Sign up for free to view info

Company overview Employee directory